Lipidated promiscuous peptides vaccine for tuberculosis-endemic regions

Trends in Molecular Medicine

Volumn 18, Issue 10, 2012, Pages 607-614

  Gowthaman, Uthaman ^a,c   Rai, Pradeep K ^a   Khan, Nargis ^a   Jackson, David C ^b   Agrewala, Javed N ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BCG; Dendritic cells; Pam2Cys; Promiscuous peptides; T cell epitopes; TB endemic area; TLR 2; Tuberculosis; Vaccine

Indexed keywords

[2,3 BIS(PALMITOYLOXY)PROPYL] CYSTEINE; ALBENDAZOLE; BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GONADORELIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 5; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PATTERN RECOGNITION RECEPTOR; PEPTIDE VACCINE; TOLL LIKE RECEPTOR 2; TUBERCULIN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ATYPICAL MYCOBACTERIUM; CELL ACTIVATION; CELLULAR IMMUNITY; CHROMATOGRAPHY; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; ENDEMIC DISEASE; GENOMICS; HELMINTHIASIS; HELPER CELL; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; MYCOBACTERIUM AVIUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM KANSASII; NONHUMAN; PROTEOMICS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATIC HEART DISEASE; TH2 CELL; TUBERCULOSIS; WART VIRUS;

ANIMALS; BCG VACCINE; CLINICAL TRIALS AS TOPIC; HELMINTHS; HUMANS; MYCOBACTERIUM; TH1 CELLS; TOLL-LIKE RECEPTOR 2; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINATION; VACCINES, SUBUNIT;

CORYNEBACTERINEAE; MYCOBACTERIUM BOVIS BCG; VERMES;

EID: 84866900148     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.07.008     Document Type: Review

References (75)

1. Kaufmann S.H., et al. New vaccines for tuberculosis. Lancet 2010, 375:2110-2119.
2. Lonnroth K., et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010, 375:1814-1829.
3. Kaufmann S.H. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010, 33:567-577.
4. World Health Forum. (1993) Tuberculosis: a global emergency. World Health Forum 14, 438.
5. Russell D.G., et al. Tuberculosis: what we don't know can, and does, hurt us. Science 2010, 328:852-856.
6. Gandhi N.R., et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375:1830-1843.
7. Gowthaman U., et al. Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T cell response. J. Infect. Dis. 2011, 204:1328-1338.
8. Andersen P., Doherty T.M. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 2005, 3:656-662.
9. Narayanan P.R. Influence of sex, age & nontuberculous infection at intake on the efficacy of BCG: re-analysis of 15-year data from a double-blind randomized control trial in South India. Ind. J. Med. Res. 2006, 123:119-124.
10. Rook G.A., et al. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?. Vaccine 2005, 23:2115-2120.
11. Barreto M.L., et al. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial. Vaccine 2011, 29:4875-4877.
12. Brewer T.F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin. Infect. Dis. 2000, 3:S64-S67.
13. Soysal A., et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005, 366:1443-1451.
14. Crampin A.C., et al. What has Karonga taught us? Tuberculosis studied over three decades. Int. J. Tuberc. Lung Dis. 2009, 13:153-164.
15. Weir R.E., et al. The influence of previous exposure to environmental mycobacteria on the interferon-γ response to Bacille Calmette-Guerin vaccination in southern England and northern Malawi. Clin. Exp. Immunol. 2006, 146:390-399.
16. Orme I.M. The Achilles heel of BCG. Tuberculosis (Edinb.) 2010, 90:329-332.
17. Sterne J.A., et al. Does the efficacy of BCG decline with time since vaccination?. Int. J. Tuberc. Lung Dis. 1998, 2:200-207.
18. Aronson N.E., et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 2004, 291:2086-2091.
19. Jaron B., et al. Effect of attenuation of Treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis. PLoS ONE 2008, 3:e2833.
20. Madura Larsen J., et al. BCG stimulated dendritic cells induce an interleukin-10 producing T cell population with no T helper 1 or T helper 2 bias in vitro. Immunology 2007, 121:276-282.
21. September S.M., et al. Diversity of nontuberculoid Mycobacterium species in biofilms of urban and semiurban drinking water distribution systems. Appl. Environ. Microbiol. 2004, 70:7571-7573.
22. Gopinath K., Singh S. Non-tuberculous mycobacteria in TB-endemic countries: are we neglecting the danger?. PLoS Negl. Trop. Dis. 2010, 4:e615.
23. Kamala T., et al. Isolation and identification of environmental mycobacteria in the Mycobacterium bovis BCG trial area of South India. Appl. Environ. Microbiol. 1994, 60:2180-2183.
24. Black G.F., et al. Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi. J. Infect. Dis. 2001, 184:322-329.
25. Rook G.A., et al. Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not. Tuberculosis (Edinb.) 2006, 86:152-162.
26. Black G.F., et al. BCG-induced increase in interferon-γ response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002, 359:1393-1401.
27. Young S.L., et al. Environmental strains of Mycobacterium avium interfere with immune responses associated with Mycobacterium bovis BCG vaccination. Infect. Immun. 2007, 75:2833-2840.
28. Brandt L., et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 2002, 70:672-678.
29. Lozes E., et al. Crossreactive immune responses against Mycobacterium bovis BCG in mice infected with non-tuberculous mycobacteria belonging to the MAIS-Group. Scand. J. Immunol. 1997, 46:16-26.
30. Wojciechowski W., et al. Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guerin involves class II transactivator and depends on the Nramp1 gene. J. Immunol. 1999, 163:2688-2696.
31. Pancholi P., et al. Sequestration from immune CD4+ T cells of mycobacteria growing in human macrophages. Science 1993, 260:984-986.
32. Sendide K., et al. Mycobacterium bovis BCG attenuates surface expression of mature class II molecules through IL-10-dependent inhibition of cathepsin S. J. Immunol. 2005, 175:5324-5332.
33. Ullrich H.J., et al. Interaction of Mycobacterium avium-containing phagosomes with the antigen presentation pathway. J. Immunol. 2000, 165:6073-6080.
34. Rook G.A., et al. Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin. Immunopathol. 2004, 25:237-255.
35. Malhotra I., et al. Helminth- and Bacillus Calmette-Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. J. Immunol. 1999, 162:6843-6848.
36. Elias D., et al. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guerin (BCG) vaccination. Clin. Exp. Immunol. 2001, 123:219-225.
37. Elias D., et al. Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. Vaccine 2005, 23:1326-1334.
38. Pearlman E., et al. Modulation of murine cytokine responses to mycobacterial antigens by helminth-induced T helper 2 cell responses. J. Immunol. 1993, 151:4857-4864.
39. Santosuosso M., et al. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun. 2006, 74:4634-4643.
40. O'Brien K.L., et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat. Med. 2009, 15:873-875.
41. Akira S., et al. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
42. Chua B.Y., et al. Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2. J. Immunol. 2011, 187:1692-1701.
43. Chua B.Y., et al. Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines. Methods Mol. Biol. 2008, 494:247-261.
44. Chua B.Y., et al. Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine 2007, 25:92-101.
45. Deliyannis G., et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur. J. Immunol. 2006, 36:770-778.
46. Jackson D.C., et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:15440-15445.
47. Jones K.L., et al. Human dendritic cells pulsed with specific lipopeptides stimulate autologous antigen-specific T cells without the addition of exogenous maturation factors. J. Viral Hepat. 2008, 15:761-772.
48. Pejoski D., et al. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol. Cell Biol. 2010, 88:605-611.
49. Torresi J., et al. Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes. Immunol. Cell Biol. 2007, 85:169-173.
50. Torresi J., et al. A self-adjuvanting multiepitope immunogen that induces a broadly crossreactive antibody to hepatitis C virus. Hepatology 2007, 45:911-920.
51. Zeng W., et al. Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. Vaccine 2005, 23:4427-4435.
52. Zeng W., et al. Lipidation of intact proteins produces highly immunogenic vaccine candidates. Mol. Immunol. 2011, 48:490-496.
53. Zeng W., et al. A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building. J. Biol. Chem. 2011, 286:12944-12951.
54. Santambrogio L., et al. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:15050-15055.
55. Allen P.M., et al. Processing of lysozyme by macrophages: identification of the determinant recognized by two T cell hybridomas. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:2489-2493.
56. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
57. Brightbill H.D., et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999, 285:732-736.
58. Iwai L.K., et al. In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals. Mol. Med. 2003, 9:209-219.
59. Klade C.S., et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008, 134:1385-1395.
60. Gowthaman U., Agrewala J.N. In silico methods for predicting T cell epitopes: Dr Jekyll or Mr Hyde?. Expert Rev. Proteomics 2009, 6:527-537.
61. Sette A., Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010, 33:530-541.
62. Chodisetti S.B., et al. Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis. BMC Immunol. 2012, 13:13.
63. Cunningham M.W. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 2000, 13:470-511.
64. Brandt E.R., et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat. Med. 2000, 6:455-459.
65. Batzloff M.R., et al. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J. Infect. Dis. 2006, 194:325-330.
66. Jackson D.C., et al. The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. Curr. Drug Targets 2002, 3:175-196.
67. Purcell A.W., et al. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 2007, 6:404-414.
68. Kenter G.G., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 2009, 361:1838-1847.
69. Cong H., et al. Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice. Hum. Immunol. 2012, 73:1-10.
70. Bafica A., et al. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J. Exp. Med. 2005, 202:1715-1724.
71. Reiling N., et al. Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J. Immunol. 2002, 169:3480-3484.
72. Stenger S., et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Pneumologie 2002, 56:103-107. (in German).
73. Liu P.T., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
74. Chandran S.S., et al. TLR2 engagement on dendritic cells promotes high frequency effector and memory CD4 T cell responses. J. Immunol. 2009, 183:7832-7841.
75. He Y., et al. Emerging vaccine informatics. J. Biomed. Biotechnol. 2010, 2010:218590.